Elixir Medical Corporation

Advanced Cardiovascular Systems, Inc.

Avantec Vascular Corporation

Avantac Vascular Corporation

John Y Yan

Vinayak D Bhat

Motasim Mahmoud Sirhan

Xiaoxia Zheng

Benjamyn Serna

Joseph Paraschac

Brett W Cryer

Kevin Gertner

Randy S Chan

David C Gale

Bin Huang

Houdin Dehnad

Joseph R Callol

Howard Huang

John M Capek

Kim Nguyen

Bozena Treadwell

Matthew Tyler Surber

An aspiration catheter includes a catheter body having a proximal end, a distal end, and an aspiration lumen therebetween. A distal segment comprising an expandable distal tip of the aspiration catheter comprises a membrane and an expandable supporting structure, such as a scaffold, configured to radially expand the expandable distal tip. The expandable supporting structure may include supporting elements and other features which increase resistance to collapse of the expandable membrane under vacuum or negative pressure applied to aspirate clot through the aspiration lumen in the expanded configuration.

Aspiration catheters with expandable distal tip

Balloon catheters, sleeves, cages, and endoluminal prostheses are provided with stress-applying and spacing features coupled to expandable surfaces thereof. The stress-applying features may have blunt and/or rounded contact regions which contact tissue or calcified regions in the vasculature. The contact regions dent or fracture occlusive material on the wall of a vascular lumen and/or patient valve leaflets when expanded. The spacing features permit blood, drug, and contrast perfusion past structures expanded in the vasculature, particularly balloon catheters.

Methods and apparatus for plaque disruption

A stent (scaffold) or other luminal prosthesis comprising circumferential structural elements which provide high strength after deployment and allows for scaffold to uncage, and/or allow for scaffold or luminal expansion thereafter. The circumferential scaffold is typically formed from non-degradable material and will be modified to expand and/or uncage after deployment.

Uncaging stent

Devices, systems, and methods are provided including a structure having one or more surfaces configured for internal use within a patient's body and one or more therapeutic compositions comprising one or more active substances including a direct factor Xa inhibitor, and a direct factor IIa inhibitor disposed in or on the structure. The structure is configured to be positioned adjacent an injury site in the patient's body. The one or more active substances optionally include an anti-proliferative agent. The therapeutic composition is formulated to release the one or more active substances to the injury site to provide one or more of inhibit clot formation, promote clot dissolution, inhibit or dissolute inflammation, inhibit vessel injury, increase time before clotting, and/or inhibit cell proliferation.

Anticoagulant compounds and methods and devices for their use

A system for reshaping a valve annulus includes an elongate template having a length along a longitudinal axis and at least one concavity in a generally lateral direction along said length. The pre-shaped template is positioned against at least a region of an inner peripheral wall of the valve annulus, and at least one anchor on the template is advanced into a lateral wall of the valve annulus to reposition at least one segment of the region of the inner peripheral wall of the valve annulus into said concavity. In this way, a peripheral length of the valve annulus can be foreshortened and/or reshaped to improve coaption of the valve leaflets and/or to eliminate or decrease regurgitation of a valve.

Methods and devices for heart valve repair

A stent (scaffold) or other luminal prosthesis comprising circumferential structural elements which provides high strength after deployment and allows for scaffold to uncage, and/or allow for scaffold or luminal expansion thereafter. The circumferential scaffold may be formed from degradable material, or may be formed from non-degradable material and will be modified to expand and/or uncage after deployment.

A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula: wherein R, R, R, R, R, R, M, M, M, M, M, Mand Mare each independently a member selected from the group consisting of H, Calkyl, OH and Chydroxyalkyl; R, Rand Rare each independently selected from the group consisting of Calkoxy and OH; Ris a member selected from the group consisting of H, &#x2014;OH, &#x2014;OP(O)Me, &#x2014;O&#x2014;(CH)&#x2014;OH and &#x2014;O&#x2014;(CH)&#x2014;O&#x2014;(CH)&#x2014;CH, wherein subscripts n and m are each independently from 2 to 8 and subscript o is from 1 to 6; each of Land Lare independently selected from the group consisting of: wherein each Mis independently a member selected from the group consisting of Calkyl, OH and Chydroxyalkyl; each of Land Lare independently selected from the group consisting of: and salts, isomers, or N-oxides thereof.

Macrocyclic lactone compounds and methods for their use

Devices and methods are provided for an implantable medical device which is degradable over a clinically relevant period of time. The medical devices may have the form of implants, graft implants, vascular implants, non vascular implants, wound closure implants, sutures, drug delivery implants, biologic delivery implants, urinary tract implants, inter-uterine implants, organ implants, bone implants including bone plates, bone screws, dental implants, spinal disks, or the like. In preferred embodiments, the implantable medical device comprises an implantable luminal prosthesis, such as vascular and non-vascular stents and stents grafts.

Degradable implantable medical devices

A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula: wherein R, R, R, R, R, R, M, M, M, M, M, Mand Mare each independently a member selected from the group consisting of H, Calkyl, OH and Chydroxyalkyl; R, Rand Rare each independently selected from the group consisting of Calkoxy and OH; Ris a member selected from the group consisting of H, &#x2014;OH, &#x2014;OP(O)Me, &#x2014;O&#x2014;(CH)&#x2014;OH and &#x2014;O&#x2014;(CH)&#x2014;O&#x2014;(CH)&#x2014;CH, wherein subscripts n and m are each independently from 2 to 8 and subscript o is from 1 to 6; each of Land Lare independently selected from the group consisting of: wherein each Mis independently a member selected from the group consisting of Calkyl, OH and Chydroxyalkyl; each of Land Lare independently selected from the group consisting of: andsalts, isomers, or N-oxides thereof.

Growing community of inventors

Los Gatos, CA, United States of America

John Y Yan